Median returns three months post IPO 2024 performance (the green line in Chart 5) were much better than the last two years (purple and pink lines). Importantly, 2024 IPOs as a group have so far held ...

Hotel101 Global—a unit of DoubleDragon, which is jointly owned by Philippine fast food giant Jollibee founder Tony Tan ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The first Israeli IPO on . Nasdaq. in 2025 is expected to take place soon, when tech company Odysight.ai (OTC: ODYS) will ...

Key Takeaways Cybersecurity firm SailPoint is reportedly targeting an IPO valuation of up to $11.5 billion.SailPoint and ...

Nasdaq reported higher fourth-quarter profit on Wednesday, helped by increased demand for the exchange operator's financial ...

SailPoint intends to use its net proceeds from this offering to repay a portion of its term loan, settle outstanding equity awards and equity appreciation rights, pay outstanding fees under the ...

Sailpoint said Thoma Bravo, which took the company private in 2022 in a deal valued at about $6.9 billion, plans to sell 2.5 million shares in the IPO, bringing the size of the offering to 50 million ...

Weight loss drug developer Metsera is targeting $289m in its Nasdaq IPO while Maze Therapeutics has outlined plans for a $131m listing, and Ascentage Pharma – already listed in Hong Kong – started ...

SailPoint said on Tuesday it was targeting a valuation of up to $11.5 billion in its New York flotation, as the cybersecurity ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

The company has been expanding outside its market-sensitive core activities of trading and listing to products that help ...